VEA
TSHA icon

Virtus ETF Advisers’s Taysha Gene Therapies TSHA Stock Holding History

Virtus ETF Advisers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,597
Closed -$54.7K – 776
2024
Q4 		$54.7K Buy
31,597
+9,494
+43% +$19.7K 0.02% 456
2024
Q3 		$44.4K Buy
22,103
+394
+2% +$864 0.02% 444
2024
Q2 		$48.6K Buy
+21,709
New +$63.2K 0.02% 444
2022
Q2 		– Sell
-10,878
Closed -$71K – 474
2022
Q1 		$71K Sell
10,878
-641
-6% -$4.79K 0.03% 349
2021
Q4 		$134K Buy
11,519
+3,251
+39% +$49K 0.05% 365
2021
Q3 		$154K Sell
8,268
-429
-5% -$8.15K 0.07% 335
2021
Q2 		$184K Buy
+8,697
New +$200K 0.08% 381

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Virtus ETF Advisers's TSHA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Taysha Gene Therapies (TSHA) in Q1 2025, closing a stake of 31,597 shares — an estimated $54.7K sold.

Virtus ETF Advisers first reported a position in TSHA in Q2 2021 and held it in 7 quarters. The position peaked at $184K in Q2 2021. 127 funds tracked by Wall St. Rank hold TSHA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Taysha Gene Therapies position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 31,597 Taysha Gene Therapies shares in Q1 2025, an estimated $54.7K.
  • Virtus ETF Advisers first reported a position in Taysha Gene Therapies in Q2 2021 and held it in 7 quarters.
  • Virtus ETF Advisers's Taysha Gene Therapies position peaked at $184K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.